The implications of antigenic diversity for vaccine development—Zolla-Pazner 1999

Human monoclonal and polyclonal anti-HIV-1 antibodies show that the immune system recognizes common epitopes, including neutralizing antibodies. An adequate HIV vaccination could elicit cross-clade neutralizing antibodies. To create such a vaccine, one must fully understand HIV's antigenic structure, establish and identify immunologic classifications for HIV, and rationally choose the minimum number and types of viruses from these immunologic groupings that will induce the broadest protective responses.

Zolla-Pazner, S., Gomy, M. K., & Nyambi, P. N. (1999). The implications of antigenic diversity for vaccine development. Immunology letters, 66(1-3), 159–164. https://doi.org/10.1016/s0165-2478(98)00176-x